The expression percentage of the TPS and CPS was developed to assess programmed death ligand 1 (PD-L1) expression and has been approved by the FDA to aid in identifying patients for immunotherapy treatment for six tumor indications at clinically confirmed CPS diagnostic limits: adenocarcinoma of the stomach or gastroesophageal junction (GC/GEJ) (CPS ≥ 1), cervical cancer (CPS ≥ 1), urothelial carcinoma (CPS ≥ 10), squamous cell carcinoma of the head and neck (HNSCC) (CPS ≥ 1), esophageal squamous cell carcinoma (ESCC) (CPS ≥ 10), and triple-negative breast cancer (TNBC) (CPS ≥ 10) [9,10]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.